Evaluation of anti-IgE antibody therapy in the patients with wheat allergy
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2016
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 22 Nov 2016 Status changed from active, no longer recruiting to completed.
- 07 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2014 New trial record